Directory >



This ADC product is composed of an anti-HER2 antibody (Trastuzumab) conjuagated via a AO-MC linker to MMAE (Trastuzumab-AO-MC-MMAE). It has demonstrated a response in breast, ovarian and lung cancer treatment by a MOA (Mechanism of Action) of Depolymerize Microtubules.

There are no comments yet. Be the first to comment

Read Next